US Stem Cell Inc (USRM)

[sdave2002]

$USRM UPDATE as of November 8th, 2017 per 10Q

Link to Journal of Clinical Medicine published November 2017 with Kristin's study. http://www.jocmr.org/index.php/JOCMR/article/view/3187

"The study, called "Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction," is the largest safety trial to date that used stem cells from fat. It was published in the Journal of Clinical Medicine Research and co-authored by U.S. Stem Cell, Inc. Chief Science Officer Kristin Comella, PhD, as well as Michelle Parlo, PA, Rosemary Daly, DO, Vincent Depasquale, DC, Eric Edgerton, DC, Patrick Mallory, DO, Roy Schmidt, MD, Walter P. Drake, PhD.
"
from study-
"Competing Interests
KC is an officer of US Stem Cell, Inc.
Funding
This study was partially funded by US Stem Cell, Inc."

Key growing financials
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
$1700k Sept 2017

Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k vs 443k last Jun 2016)
$1507k Sept 2017 (Gross profit now $1024k vs $397k last Sept 2016)

Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
$957k Sept 2017


Share Structure
341,284,823 shares issues and outstanding as of Nov 2017
337,417,859 shares issued and outstanding as of Sept 2017
336,461,515 shares issued and outstanding as of June 2017


Kuwait Clinic
"The US Stem Cell Clinic in Kuwait is currently under construction and is expected to open before the end of the year" Page 31 of recent 10 Q
There are Job postings/ Job descriptions on USRM's websites, for the Kuwait clinic. I am guessing this means they will have some ownership with the Kuwait clinic thus another big source of revenue.

Customers
"As of September 30, 2017, four customers, one of which is a related party ( US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest), represented 25%, 15%, 16%, and 21% of accounts receivable, respectively, representing an aggregate of 77% of the Company’s accounts receivable. As of December 31, 2016, four customers, one of which is the same related party above, represented 45%, 13%, 13%, and 12% of accounts receivable respectively, representing, an aggregate of 83%, of the Company’s accounts receivable."

4 Customers responsible for so much business is very normal, 80/20 applies to most businesses and for USRM is seems that the 4 customer's percentage is shrinking, overall, showing growth with other customers while revenues increasing. Very good sign. (Those four customers don't mean four clinics)

Compliance

US Stem Cell Clinic, LLC, (“SCC”), a partially owned investment of our company (in which we have a 33% member interest), is a physician run regenerative medicine/cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases. SCC is operating in compliance with the FDA 1271s which allow for same day medical procedures to be considered the practice of medicine. We isolate stem cells from bone marrow and adipose tissue and also utilize platelet rich plasma.

Market Growth

"According to the Scalar Market Research Stem Cell Therapy Analysis Global Revenue, Trends, Growth, Share, Size and Forecast to 2022, the stem cell therapy market is worth USD 11.99 billion in 2016 and is expected to reach USD 60.94 billion by 2022, growing at a CAGR of 31.1% from 2016 to 2022." per page 30 of recent 10Q


Link to articles
http://www.baystreet.ca/viewarticle.aspx?id=480636
http://us-stemcell.com/us-stem-cell-reports-3q/